Latest Levodopa-Induced Dyskinesia Stories

EMERYVILLE, Calif., April 22, 2013 /PRNewswire/ -- Adamas Pharmaceuticals, Inc. announced today that the United States Patent and Trademark Office (USPTO) issued U.S. Patent No. 8,389,578 entitled "Composition and method for treatment of neurological disease." The claims of this invention are directed towards improved methods for treating Parkinson's disease using extended-release amantadine, and cover key features related to the dose strength and pharmacokinetic profile. Nurelin -...

U.S. and European Surveyed Neurologists Agree that Better Treatment for Motor Response Complications Remains as an Unmet Need in Parkinson's Disease, According to a New Report from Decision Resources BURLINGTON, Mass., April 17, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that surveyed U.S. neurologists indicate that the most important drug attribute for a therapy targeting...

EMERYVILLE, Calif., March 20, 2013 /PRNewswire/-- Adamas Pharmaceuticals, Inc. will present research results today from its Nurelin(TM )(amantadine HCl extended release capsules) program demonstrating the benefit of amantadine in traumatic brain injury (TBI) at the 65(th) American Academy of Neurology (AAN) Annual Meeting being held in San Diego, CA. Nurelin, a once-daily extended release formulation of amantadine intended for nighttime administration, is being evaluated in a Phase...

KALAMAZOO, Mich., Feb. 7, 2013 /PRNewswire/ -- Metabolic Solutions Development Company, LLC (MSDC) announced today that it has received an award from The Michael J. Fox Foundation for Parkinson's Research (MJFF) to conduct preclinical research on a first-in-class mTOT Modulator, MSDC-0160, as a potential treatment for levodopa induced dyskinesia (LID). The study will be undertaken in collaboration with Patrik Brundin, MD, PhD, of Van Andel Institute (VAI). The aim of the study,...

NEW BRUNSWICK, N.J., Jan. 25, 2013 /PRNewswire-USNewswire/ -- Parkinson's disease affects one million people in the United States and seven million worldwide. While L-Dopa is effective in treating the disease symptoms, the vast majority of patients taking it chronically eventually develop L-Dopa Induced Dyskinesia (LID), abnormal involuntary movements that can be disabling. A new company, MentiNova, Inc., is exploring an oral medication that could reduce these uncontrollable, often...

EMERYVILLE, Calif., June 4, 2012 /PRNewswire/ -- Adamas Pharmaceuticals, Inc., a privately held company, announced today that it will present an update on its Nurelin(TM)( )(amantadine HCl extended release capsules) program at the Cambridge Healthtech Institute's (CHI) Targeting Parkinson's Disease Symposium being held today in Philadelphia. Nurelin, a once-daily extended release formulation of amantadine intended for night-time administration, is being developed for the treatment of...